CLINICAL CARE CROSSROADS
NAVIGATING THE INTERSECTION OF HEART FAILURE AND DIABETES

SATURDAY, SEPTEMBER 16
REGISTRATION & LUNCH: 12:00 PM – 12:15 PM | PROGRAM: 12:15 PM – 2:15 PM
VENUE: GAYLORD TEXAN HOTEL, 1501 GAYLORD TRAIL, GRAPEVINE, TEXAS | ROOM: TEXAS D

MODERATOR
Paul J. Hauptman, MD
Professor of Medicine
Saint Louis University School of Medicine
St. Louis, Missouri

PANELISTS
James C. Fang, MD
Professor of Medicine
Chief, Cardiovascular Division
John and June B. Hartman Presidential Endowed Chair
Executive Director, Cardiovascular Service Line
Salt Lake City, Utah

Lawrence Blonde, MD
Director, Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, Louisiana

James L. Januzzi, MD
Hutter Family Professor of Medicine
Division of Cardiology
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

AGENDA
12:00 PM – 12:15 PM
Registration and Seating

12:15 PM – 12:20 PM
Welcome and Introduction
Paul J. Hauptman, MD

12:20 PM – 12:40 PM
Heart Failure and Diabetes: Double the Trouble
James C. Fang, MD

12:40 PM – 1:00 PM
Emerging Effects of Diabetes Therapies in HF: Outside Perspectives
Lawrence Blonde, MD

1:00 PM – 1:20 PM
Tailoring Treatment for HF and Diabetes: A Challenge in Comorbidities
James L. Januzzi, MD

1:20 PM – 1:40 PM
Complex Cases in HF: A Crossfire Debate
Paul J. Hauptman, MD

1:40 PM – 2:10 PM
Faculty Discussion/Q&A

2:10 PM – 2:15 PM
Concluding Remarks
Paul J. Hauptman, MD

Target Audience
This activity is intended for cardiologists, primary care physicians, and diabetologists/endocrinologists.

Goal Statement
The goal of this program is to review the relationship between diabetes and heart failure (HF), discuss recent data from cardiovascular (CV) outcomes trials on the potential benefits of type 2 diabetes (T2D) therapies in patients who have or are at risk for HF, and discuss tailoring treatment in patients presenting with HF and diabetes to optimize outcomes.

Learning Objectives
Upon completion of this activity, participants will be able to:
• Identify mechanisms linking HF and diabetes.
• Apply recent heart failure-related CV data for T2D therapies.
• Create an individualized, safe approach to addressing diabetes in patients with heart failure.
• Select treatments for patients with HF to address patient comorbidities and disease progression.

Accreditation Statement
Physicians:
The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Heart Failure Society of America designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please call HFSA at 301-312-8635 for more information about contact hours.

Medscape Education
Supported by independent educational grants from AstraZeneca and Eli Lilly USA, LLC and Boehringer Ingelheim Pharmaceuticals, Inc.

To register, please visit: www.medscape.org/townhall/hf-diabetes-registration

Registration for the 21st Annual Scientific Meeting and an official name badge are required to attend this symposium.

Accredited Sponsor: Heart Failure Society of America